Loss of exclusivity · US · 2034
Drugs going off patent in 2034
Which drugs go off patent in 2034?
One blockbuster drug with about $4.9B in 2025 worldwide sales loses US exclusivity in 2034: Vabysmo (Roche).
- Drugs losing US exclusivity
- 18 years from now
- 2025 worldwide sales
- ≈$4.9B#12 of 13 years tracked
- Largest drug
- VabysmoRoche · $4.9B
- Most exposed company
- Roche6.7% of 2025 revenue
The 1 drug
This date is estimated from patent expiry and could move. Each drug's page has the sources.
Companies most exposed in 2034
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
What to expect
Biosimilars usually erode a biologic's sales more gradually, because they are harder to make and switching takes longer.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →
Share, cite or embed
Cite
Pharma Patent Cliff by readouts.io. "Drugs going off patent in 2034." Updated 8 October 2026. https://pharmapatentcliff.com/off-patent/2034
Embed
Free to use on your site with the source link. It shows the latest data whenever the page loads.